PetroTech Oil and Gas Inc. (OTC: PTOG) announced the week that they have set up a subsidiary company in Colorado, and Washington, to serve as the foundation for the company's entry into the emerging market for medical and recently legalized recreational marijuana in the United States. PTOG will leverage its expertise in natural resource development in enhanced oil recovery and launch LP.US Management Group, Inc. The partnership allows The Company to secure a leadership position in the rapidly developing marketplace around legalized Cannabis and Hemp production. LP U.S. Management Group, Inc. which owns (http://www.legalizepot.us) is structured around three main divisions, including Entertainment Arts, Information and News, and Cannabis and Hemp Production. These divisions will work cohesively to produce and market medicinal and recreational marijuana, as well as the many fiber, oil and seed related Hemp products produced for home and commercial use. The Company is acquiring warehouse facilities in Telluride, CO, and currently has three growers in Colorado and two in Washington, with immediate plans for expansion already formalized.

Tanke, Incorporated (OTC: TNKE), a diversified holding company focused on emerging technologies and "cleantech" is pleased to announced this week the signing of an incubation, management and investment agreement with Xinyue Coating and Finishing Ltd., a company headquartered in Jiaxing City, China. The agreement is expected to bring management revenues of $4.8 million in 2014 and additional incubation and investment revenues of $60 million.

Strategic Global Investments, Inc. (OTC: STBV) is pleased to announce that the Company has completed negotiations, and has signed an agreement for the purchase of Bearpot, Inc., controlling entity of an existing Marijuana Growing facility located in Teller County, Colorado. As a subsidiary of Strategic Global Inc., Bearpot, Inc. will function as the marijuana incubation and development sector of the Company. The transaction brings existing equipment and inventory; creating a successful model that the Company can duplicate as legalization continues to spread and markets continue to open nationwide and in Canada.

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) today announced top line results from a planned 18 month analysis of an ongoing 3 year Phase 2/3 clinical trial of RP103 (delayed-release cysteamine) for the potential treatment of Huntington's disease (HD) in collaboration with the Centre Hospitalier Universitaire d'Angers (CHU d'Angers). A total of 96 patients with HD were randomized to treatment with RP103 or placebo. Eighty nine patients completed the initial 18 month phase. Analysis of all 96 patients enrolled in the trial showed a positive trend towards slower progression of Total Motor Score (TMS) in patients treated with RP103 vs. those patients on placebo, the primary endpoint of the study.

Agenus Inc. (NASDAQ: AGEN), a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company. The acquisition includes the Retrocyte Display® technology platform which enables rapid discovery and optimization of fully human antibodies against a wide array of molecular targets. For the past three years, 4-Antibody has been applying Retrocyte Display to create therapeutic antibodies to six key checkpoint targets that regulate immune response to cancers and other diseases. The company has multiple preclinical immune CPM programs in development..

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNMG has been compensated one thousand five hundred fifty dollars for news coverage of the current press release issued by PTOG by a non-affiliated third party.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.